Movement disorders : official journal of the Movement Disorder Society
-
Randomized Controlled Trial Multicenter Study
Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
This study's aims were to determine the efficacy and tolerability of rasagiline, a selective monoamine oxidase inhibitor B, for PD patients with mild cognitive impairment. ⋯ Rasagiline treatment in PD patients with mild cognitive impairment was not associated with cognitive improvement. Rasagiline did not worsen cognition, improved motor symptoms and activities of daily living, and was well tolerated in elderly cognitively impaired patients. © 2016 International Parkinson and Movement Disorder Society.